GlassScriptPhysician profile
Jamie D Paranicas
NPI 1528173606
$7,303.91
in general payments reported to CMS, 2019-2025
27 companies · $1,492 in 2025
The $1,492 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,654 · 2020: $567 · 2021: $537 · 2022: $912 · 2023: $1,004 · 2024: $1,139 · 2025: $1,492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,634.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,528.22 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, General - Therapies, Cds - Mct/Cem Monitoring |
| Pfizer INC. | $993.47 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $717.13 | 2020-2025 | Lokelma, Brilinta, Farxiga |
| Novartis Pharmaceuticals Corporation | $637.99 | 2019-2025 | |
| Amgen INC. | $468.33 | 2019-2025 | Repatha |
| Esperion Therapeutics, INC. | $386.13 | 2020-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $349.31 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $294.59 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $229.49 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Merck Sharp & Dohme LLC | $209.84 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $208.89 | 2019-2024 | Eliquis |
| Scpharmaceuticals INC. | $202.52 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $186.35 | 2019 | |
| Amarin Pharma, INC. | $168.07 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.23 | 2019-2025 | Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $112.69 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $68.79 | 2023 | Inpefa |
| Kowa Pharmaceuticals America, INC. | $66.09 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $58.81 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $45.75 | 2021-2025 | Opsumit, Uptravi |
| Kiniksa Pharmaceuticals International, Plc | $44.26 | 2024 | Arcalyst |
| Lundbeck LLC | $37.15 | 2019 | |
| Alnylam Pharmaceuticals INC. | $34.33 | 2025 | Amvuttra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.37 | 2019-2020 | |
| Heartflow, INC. | $27.46 | 2025 | |
| Vifor Pharma, INC. | $24.64 | 2019 | |
| Acarix USA INC. | $15.01 | 2023 | Cadscor System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Paranicas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.